-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, CHiy3fYdjsCBQrHTqF9tUnFFNunuMqDCGUEG2djPDgrgxicDrEzRrH7H1KEiYF3E 1GrGSezJWMpgZrh1BiEZ8g== 0000892569-01-501324.txt : 20020413 0000892569-01-501324.hdr.sgml : 20020413 ACCESSION NUMBER: 0000892569-01-501324 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20011220 ITEM INFORMATION: Other events ITEM INFORMATION: Financial statements and exhibits FILED AS OF DATE: 20011220 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NEOTHERAPEUTICS INC CENTRAL INDEX KEY: 0000831547 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 930979187 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-28782 FILM NUMBER: 1818741 BUSINESS ADDRESS: STREET 1: 157 TECHNOLOGY DR STREET 2: STE J-821 CITY: IRVINE STATE: CA ZIP: 92618 BUSINESS PHONE: 9497886700 MAIL ADDRESS: STREET 1: 157 TECHNOLOGY DR STREET 2: STE J-821 CITY: IRVINE STATE: CA ZIP: 92618 FORMER COMPANY: FORMER CONFORMED NAME: AMERICUS FUNDING CORP DATE OF NAME CHANGE: 19920703 8-K 1 a78014e8-k.txt FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 -------------------- FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES AND EXCHANGE ACT OF 1934 December 20, 2001 Date of Report (Date of earliest event reported) -------------------- NEOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) DELAWARE 000-28782 93-0979187 (State or other Jurisdiction (Commission File Number) (IRS Employer of Incorporation) Identification Number) 157 TECHNOLOGY DRIVE 92618 IRVINE, CALIFORNIA (Zip Code) (Address of principal executive offices)
(949) 788-6700 (Registrant's telephone number, including area code) N/A (Former Name or Former Address, if Changed Since Last Report) ITEM 5. OTHER EVENTS. On December 20, 2001, NeoTherapeutics, Inc. issued a news release announcing that it's subsidiary, NeoGene Technologies, entered into a second license agreement with Pfizer Inc. for the use of an orphan receptor identified by NeoGene. The text of the press release is set forth in Exhibit 99.1 attached to this report and incorporated herein by this reference. ITEM 7. EXHIBITS Exhibits: 99.1 Press Release dated December 20, 2001. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEOTHERAPEUTICS, INC. Date: December 20, 2001 By: /s/ Samuel Gulko -------------------------- Name: Samuel Gulko Title: Senior Vice President, Finance, Chief Financial Officer, Secretary and Treasurer
Exhibit Number Document Description - ------ -------------------- 99.1 Press Release dated December 20, 2001.
EX-99.1 3 a78014ex99-1.txt EXHIBIT 99.1 EXHIBIT 99.1 [NEOTHERAPEUTICS LOGO] Contacts: MEDIA RELATIONS INVESTOR RELATIONS Jon Siegal John McManus Ronald Trahan Associates (RTA) Inc. NeoTherapeutics, Inc. (508) 647-9782, ext. 15 (949) 788-6700, ext. 247 NEOTHERAPEUTICS SIGNS SECOND LICENSE AGREEMENT WITH PFIZER FOR USE OF AN ORPHAN RECEPTOR IDENTIFIED BY ITS NEOGENE TECHNOLOGIES SUBSIDIARY IRVINE, Calif., December 20, 2001 -- NeoTherapeutics, Inc. (NASDAQ: NEOT) announced today that its genomics division has entered into an agreement with Pfizer Inc (NYSE: PFE). This is the second agreement that Pfizer has signed with NeoGene this year. Under the terms of the additional agreement, NeoTherapeutics will receive an initial payment and milestone payments similar to the previous agreement. "This second agreement between NeoTherapeutics and Pfizer confirms the potential pharmaceutical value of our research findings", stated Olivier Civelli, Ph.D., Principal Investigator for NeoGene Technologies. "We are pleased that Pfizer has decided to in-license a second system for development." "We are pleased to expand our relationship with Pfizer, and are excited about the potential that we believe these receptor systems represent as targets for discovery of pharmaceutical products", stated Alvin J. Glasky, Ph.D., Chairman and Chief Executive Officer of NeoTherapeutics. "NeoGene's scientific team leads the world in the identification of orphan receptors, which represent very valuable tools for developing new drug candidates, and we hope to further demonstrate the value of their discoveries and capabilities through additional license agreements and research alliances." NeoGene's expertise relates to the largest family of receptors in the human body called the G-protein-coupled receptors (GPCRs). The GPCRs direct many of the physiological functions that are of pharmaceutical interest. Since about half of the drugs that are marketed at present act on GPCR's, the Company expects that many drugs in the future will act on unknown GPCR's or "orphan" receptors. NeoGene has placed itself at the forefront of future pharmaceutical research in its efforts to identify the function of the approximately 140 remaining orphan receptors. more... 2 NeoTherapeutics seeks to create value for stockholders through the discovery and development of central nervous system (CNS) drugs, in-licensing and commercialization of anti-cancer drugs, and the licensing out of new drug targets discovered through genomics research. The Company has two drugs addressing major medical needs in pivotal/phase 3 stage of development: Neotrofin(TM) for Alzheimer's disease and Satraplatin for prostate cancer. Additional neurology and anti-cancer drugs such are in phase 1 and 2 human clinical trials and the Company has a rich pipeline of pre-clinical drug candidates. For additional information visit the Company's web site at www.neot.com. This press release may contain forward-looking statements regarding future events and the future performance of NeoTherapeutics that involve risks and uncertainties that could cause actual results to differ materially. These risks are described in further detail in the Company's reports filed with the Securities and Exchange Commission. # # # -----END PRIVACY-ENHANCED MESSAGE-----